Many medical technologies never realize their full potential because the factors that limit broad adoption are not fully understood and addressed. This is why many technologies realize no more than 15-20% of their true potential, despite massive investments and nearly heroic efforts of the sales, marketing and leadership teams.
One of the biggest issues today in medical technology is not regulatory, or reimbursement, or the burden of clinical evidence; it is the lack of a sufficiently clear understanding of the market and market dynamics.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Heart Rhythm Society annual meeting is arguably the most important conference for big cardiac medical device makers like Medtronic Inc. (NYSE: MDT), based in Fridley, Minn., and Boston Scientific Corp. (NYSE: BSX). It’s an ideal forum for companies to release significant clinical data: Medtronic, for example, Thursday demonstrated methods to reduce accidental shocks from […]